Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Microbiol Infect ; 24(7): 755-763, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29408333

RESUMO

OBJECTIVE: Our objective was to describe the risk of hospital admission for virologically confirmed dengue (VCD) and the risk of clinically severe hospitalized VCD occurring up to 4 years after the first dose (years 1 to 4) in three randomized clinical trials comparing tetravalent dengue vaccine with placebo. METHODS: The relative risks (RR) for hospitalized VCD from first dose to year 4 were estimated by year and age-group in individual and combined studies. RESULTS: Overall, from Year 1 to Year 4, 233 and 228 participants had at least one episode of hospitalized VCD in the vaccinated (n = 22 603) and placebo (n = 11 301) groups, respectively (RR = 0.511, 95% CI 0.42-0.62). Among these, 48 and 47 cases, respectively, were classified as clinically severe. In children aged ≥9 years, 88 and 136 participants had at least one episode of hospitalized VCD in the vaccinated (n = 17 629) and placebo (n = 8821) groups, respectively (RR = 0.324; 95% CI 0.24-0.43). In vaccinated participants aged <9 years, particularly in those aged 2-5 years, there were more hospitalized VCD cases compared with the control participants in Year 3 but not in Year 4. The overall RR in those aged <9 years for Year 1 to Year 4 was 0.786 (95% CI 0.60-1.03), with a higher protective effect in the 6-8 year olds than in the 2-5 year olds. CONCLUSIONS: The overall benefit-risk remained positive in those aged ≥9 years up to year 4, although the protective effect was lower in years 3 and 4 than in years 1 and 2.


Assuntos
Vacinas contra Dengue/imunologia , Vírus da Dengue/imunologia , Dengue/prevenção & controle , Vacinas Atenuadas/imunologia , Adolescente , Anticorpos Antivirais/sangue , Ásia/epidemiologia , Criança , Pré-Escolar , Dengue/epidemiologia , Feminino , Seguimentos , Hospitalização/estatística & dados numéricos , Humanos , América Latina/epidemiologia , Masculino , Ensaios Clínicos Controlados Aleatórios como Assunto , Risco , Sorogrupo , Viremia
2.
Clin Diagn Lab Immunol ; 7(3): 501-3, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10799468

RESUMO

We examined stool samples from travelers for secretory immunoglobulin A (sIgA) to enteroaggregative Escherichia coli (EAEC) during episodes of acute diarrhea. Ten paired samples from 10 patients with diarrhea caused by EAEC were examined for the presence of specific sIgA by dot blot and Western blot immunoassays. Five samples were positive by dot blotting, and two samples were positive by Western blotting.


Assuntos
Diarreia/diagnóstico , Infecções por Escherichia coli/diagnóstico , Imunoglobulina A/análise , Adulto , Antígenos de Bactérias/análise , Antígenos de Bactérias/imunologia , Western Blotting , Doença Crônica , Diarreia/imunologia , Infecções por Escherichia coli/imunologia , Fezes/microbiologia , Humanos , Immunoblotting , Intestinos/imunologia , México , Viagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA